Unknown

Dataset Information

0

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

ABSTRACT: The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R (2) between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.

SUBMITTER: Paoletti X 

PROVIDER: S-EPMC4994928 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the predict  ...[more]

Similar Datasets

Unknown Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.
| S-EPMC4202244 | biostudies-literature
Unknown Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.
| S-EPMC6080081 | biostudies-literature
Unknown Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review.
| S-EPMC7250908 | biostudies-literature
Unknown Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer.
| S-EPMC4410904 | biostudies-literature
Unknown Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
| S-EPMC7796103 | biostudies-literature
Unknown Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
| S-EPMC8834538 | biostudies-literature
Unknown Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.
| S-EPMC5438734 | biostudies-literature
Unknown Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma.
| S-EPMC9239497 | biostudies-literature
Unknown Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
| S-EPMC9921746 | biostudies-literature
Unknown Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma.
| S-EPMC9582670 | biostudies-literature